Prothena News

Pinning Down Prothena Corporation Plc's (NASDAQ:PRTA) P/S Is Difficult Right Now

It's not a stretch to say that Prothena Corporation plc's (NASDAQ:PRTA) price-to-sales (or "P/S") ratio of 12.3x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in t

Simply Wall StJun 12 07:45 ET

Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod

Yahoo FinanceJun 11 09:29 ET

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

Yahoo FinanceJun 7 11:30 ET

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

Yahoo FinanceMay 29 10:26 ET

Buy Rating Affirmed for Prothena Amid Strong Pipeline Prospects and Strategic Partnerships

TipRanksMay 29 08:05 ET

Prothena (PRTA) Receives a Buy From Piper Sandler

TipRanksMay 29 07:06 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX), Bioxcel Therapeutics (BTAI) and Prothena (PRTA)

TipRanksMay 29 00:30 ET

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

1851 ET - Bristol Myers Squibb is not done bolstering its neuroscience portfolio after splashing cash last year. Biotechnology company Prothena says Bristol Myers has opted to obtain the exclusive glo

WSJMay 28 18:51 ET

Bristol Myers Licenses Second Compound From Prothena

Seeking AlphaMay 28 16:23 ET

Express News | Prothena to Receive $80 Million From Bristol Myers Squibb for Exclusive Global License to PRX019; Phase 1 Clinical Trial to Begin in 2024

BenzingaMay 28 16:08 ET

Express News | Prothena Corporation PLC - Prothena Also Will Be Eligible to Receive Tiered Royalties on Net Sales

ReutersMay 28 16:06 ET

Express News | Prothena Corporation PLC - Will Be Eligible to Receive Additional Development, Regulatory, and Sales Milestone Payments of up to $617.5 Mln

ReutersMay 28 16:06 ET

Express News | Prothena Corporation PLC - Prothena Will Initiate a Phase 1 Clinical Trial for Prx019 in 2024

ReutersMay 28 16:05 ET

Express News | Prothena Corporation PLC - Prothena to Receive $80 Mln From Bristol Myers Squibb for Exclusive Global License to Prx019

ReutersMay 28 16:05 ET

Express News | Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for Prx019, the Second Program From Global Neuroscience Research and Development Collaboration

ReutersMay 28 16:05 ET

Prothena Shareholders Approve Incentives and Governance Measures

TipRanksMay 17 16:22 ET

News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation Plc (NASDAQ:PRTA) Forecasts

Yahoo FinanceMay 14 06:38 ET

Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look

Seeking AlphaMay 12 11:00 ET

Analysts Have Lowered Expectations For Prothena Corporation Plc (NASDAQ:PRTA) After Its Latest Results

Yahoo FinanceMay 12 08:05 ET

Express News | Prothena Corporation PLC : Oppenheimer Cuts Target Price to $66 From $80

ReutersMay 10 08:19 ET